Corient Private Wealth LLC Raises Stock Position in Geron Co. (NASDAQ:GERN)

Corient Private Wealth LLC boosted its position in shares of Geron Co. (NASDAQ:GERN) by 58.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 37,585 shares of the biopharmaceutical company’s stock after acquiring an additional 13,896 shares during the period. Corient Private Wealth LLC’s holdings in Geron were worth $133,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. acquired a new position in shares of Geron during the fourth quarter worth $28,000. Readystate Asset Management LP acquired a new position in Geron during the 3rd quarter valued at about $58,000. Rovin Capital UT ADV increased its position in Geron by 26.9% during the 4th quarter. Rovin Capital UT ADV now owns 17,270 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 3,660 shares in the last quarter. Monterey Private Wealth Inc. purchased a new stake in Geron in the fourth quarter valued at about $63,000. Finally, KBC Group NV boosted its holdings in Geron by 45.1% in the fourth quarter. KBC Group NV now owns 24,414 shares of the biopharmaceutical company’s stock worth $86,000 after acquiring an additional 7,592 shares in the last quarter. 73.71% of the stock is currently owned by institutional investors and hedge funds.

Geron Price Performance

NASDAQ:GERN opened at $1.48 on Wednesday. The firm’s fifty day moving average is $2.24 and its two-hundred day moving average is $3.33. The firm has a market cap of $942.62 million, a price-to-earnings ratio of -4.63 and a beta of 0.54. Geron Co. has a one year low of $1.45 and a one year high of $5.34. The company has a debt-to-equity ratio of 0.04, a quick ratio of 2.74 and a current ratio of 2.89.

Geron (NASDAQ:GERN) last issued its earnings results on Wednesday, February 26th. The biopharmaceutical company reported ($0.04) EPS for the quarter, hitting analysts’ consensus estimates of ($0.04). The firm had revenue of $47.54 million for the quarter, compared to the consensus estimate of $45.29 million. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. Research analysts expect that Geron Co. will post -0.25 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on GERN shares. Barclays restated an “overweight” rating and set a $4.00 price objective (down previously from $9.00) on shares of Geron in a report on Thursday, February 27th. Scotiabank cut their price target on shares of Geron from $6.00 to $4.00 and set a “sector outperform” rating on the stock in a research note on Thursday, February 27th. Needham & Company LLC reaffirmed a “buy” rating and issued a $5.00 price target on shares of Geron in a report on Wednesday, March 12th. Stifel Nicolaus dropped their price objective on shares of Geron from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Finally, HC Wainwright restated a “neutral” rating on shares of Geron in a research note on Wednesday, March 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $5.75.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.